Cipla To Recalibrate US Investments
A More Measured Approach To US Generic R&D And Specialty
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
